Intellia Therapeutics (NTLA) Misses Q4 EPS by 9c, Revenues Miss

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($0.69), $0.09 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $6.6 million versus the consensus estimate of $14.09 million.

“Intellia’s achievements in 2020 reflect important progress on both our full-spectrum strategy and our mission to deliver curative genome editing treatments for people with severe diseases. Dosing our first patient with NTLA-2001, the first-ever systemically delivered CRISPR-based therapy, was a major milestone for our team, as we completed our transition to a clinical-stage company in the fourth quarter,” said Intellia President and Chief Executive Officer, John Leonard, M.D. “Looking ahead, we are focused on our three core priorities for 2021: clinical validation of our approach with NTLA-2001, advancement and expansion of our in vivo and ex vivo pipeline, and continued platform innovation. We have made steady progress in our global Phase 1 study of NTLA-2001 and look forward to sharing our first clinical data this year. Additionally, we are on track to submit first-in-human regulatory applications to begin clinical studies of NTLA-5001 for AML and NTLA-2002 for HAE, and we plan to nominate at least one new development candidate from our research portfolio.”

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Visa (V) Tops Q2 EPS by 7c, offers guidance
• Range Resources (RRC) Tops Q1 EPS by 11c; offers production guidance